Biodegradable Monometallic Manganese Nanoparticles for Multimodal Tumor Therapy.

Authors

Gang Shu, Chenya Wang, Zhenxing Sun, Jinbin Pan, Cai Zhang, Jiaojiao Yu, Xiang Jing, Yan Zhou, Zhuang Liu, Shao-Kai Sun

Published in

Advanced healthcare materials. Nov 01, 2026. Epub Nov 01, 2026.

Abstract

Synergistic therapeutic nanoplatforms are of considerable interest in tumor therapy, but their translational potential is often limited by complex multicomponent designs and unknown in vivo degradation behavior. Herein, we show a degradable, single-component manganese nanoparticles (Mn NPs) using liquid-phase exfoliation of commercial bulk manganese powder for cancer therapy. In the acidic tumor environment, Mn NPs react with H⁺ to generate Mn²⁺ and H₂ and raise the local pH. The released Mn²⁺ drives Fenton-like reactions to produce ROS, while H₂ causes mitochondrial damage, which together lead to tumor cell death. In addition, Mn²⁺ activates cGAS-STING signaling and initiates antitumor immunity. Moreover, Mn NPs inhibit tumor growth in CT26, 4T1, and B16F10 mouse models and show better effects than Mn²⁺ alone. Transcriptomic analysis further reveals activation of multiple immune-related signaling pathways following Mn NP treatment. In a bilateral tumor model, unilateral injection of Mn NPs triggers a systemic antitumor immune response, leading to effective inhibition of distant, untreated tumor growth. Collectively, this study identifies Mn NPs as a simple, biodegradable, single-component nanoplatform that offers a promising new route for multimodal tumor therapy.

PMID:
42967870
Bibliographic data and abstract were imported from PubMed on 02 Nov 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.